Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
recurrent, or metastatic cervical cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0292-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Details
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab
in combination with chemotherapy with or without bevacizumab, for the
treatment of adult patients with persistent, recurrent, or metastatic cervical
cancer whose tumors express PD-L1 (CPS=1) as determined by a validated test.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Gynecology
Indications:
Pembrolizumab
in combination with chemotherapy with or without bevacizumab, for the
treatment of adult patients with persistent, recurrent, or metastatic cervical
cancer whose tumors express PD-L1 (CPS=1) as determined by a validated
test.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.